Cargando…
Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use
The aim of this study was to perform a preformulation study of dexamethasone (DXM)-loaded nanostructured lipid carriers (NLCs) for ocular use. Lipid screening was applied to find the most suitable solid and liquid lipids and surfactant for the NLC formulation. The visual observation was proved with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955972/ https://www.ncbi.nlm.nih.gov/pubmed/31847336 http://dx.doi.org/10.3390/pharmaceutics11120679 |
_version_ | 1783487052461899776 |
---|---|
author | L. Kiss, Eszter Berkó, Szilvia Gácsi, Attila Kovács, Anita Katona, Gábor Soós, Judit Csányi, Erzsébet Gróf, Ilona Harazin, András Deli, Mária A. Budai-Szűcs, Mária |
author_facet | L. Kiss, Eszter Berkó, Szilvia Gácsi, Attila Kovács, Anita Katona, Gábor Soós, Judit Csányi, Erzsébet Gróf, Ilona Harazin, András Deli, Mária A. Budai-Szűcs, Mária |
author_sort | L. Kiss, Eszter |
collection | PubMed |
description | The aim of this study was to perform a preformulation study of dexamethasone (DXM)-loaded nanostructured lipid carriers (NLCs) for ocular use. Lipid screening was applied to find the most suitable solid and liquid lipids and surfactant for the NLC formulation. The visual observation was proved with XRD measurements for the establishment of the soluble state of DXM. Thermoanalytical measurements indicated that the most relevant depression of the crystallinity index could be ensured when using a 7:3 solid lipid:oil ratio. In order to optimize the NLC composition, a 2(3) full factorial experimental design was used. It was established that each independent factor (lipid, DXM, and surfactant concentration) had a significant effect on the particle size while in the case of entrapment efficiency, the DXM and surfactant concentrations were significant. Lower surfactant and lipid concentrations could be beneficial because the stability and the entrapment efficacy of NLCs were more favorable. The toxicity tests on human cornea cells indicated good ophthalmic tolerability of NLCs. The in vitro drug release study predicted a higher concentration of the solute DXM on the eye surface while the Raman mapping penetration study on the porcine cornea showed a high concentration of nanocarriers in the hydrophylic stroma layer. |
format | Online Article Text |
id | pubmed-6955972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69559722020-01-23 Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use L. Kiss, Eszter Berkó, Szilvia Gácsi, Attila Kovács, Anita Katona, Gábor Soós, Judit Csányi, Erzsébet Gróf, Ilona Harazin, András Deli, Mária A. Budai-Szűcs, Mária Pharmaceutics Article The aim of this study was to perform a preformulation study of dexamethasone (DXM)-loaded nanostructured lipid carriers (NLCs) for ocular use. Lipid screening was applied to find the most suitable solid and liquid lipids and surfactant for the NLC formulation. The visual observation was proved with XRD measurements for the establishment of the soluble state of DXM. Thermoanalytical measurements indicated that the most relevant depression of the crystallinity index could be ensured when using a 7:3 solid lipid:oil ratio. In order to optimize the NLC composition, a 2(3) full factorial experimental design was used. It was established that each independent factor (lipid, DXM, and surfactant concentration) had a significant effect on the particle size while in the case of entrapment efficiency, the DXM and surfactant concentrations were significant. Lower surfactant and lipid concentrations could be beneficial because the stability and the entrapment efficacy of NLCs were more favorable. The toxicity tests on human cornea cells indicated good ophthalmic tolerability of NLCs. The in vitro drug release study predicted a higher concentration of the solute DXM on the eye surface while the Raman mapping penetration study on the porcine cornea showed a high concentration of nanocarriers in the hydrophylic stroma layer. MDPI 2019-12-14 /pmc/articles/PMC6955972/ /pubmed/31847336 http://dx.doi.org/10.3390/pharmaceutics11120679 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article L. Kiss, Eszter Berkó, Szilvia Gácsi, Attila Kovács, Anita Katona, Gábor Soós, Judit Csányi, Erzsébet Gróf, Ilona Harazin, András Deli, Mária A. Budai-Szűcs, Mária Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use |
title | Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use |
title_full | Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use |
title_fullStr | Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use |
title_full_unstemmed | Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use |
title_short | Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use |
title_sort | design and optimization of nanostructured lipid carrier containing dexamethasone for ophthalmic use |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955972/ https://www.ncbi.nlm.nih.gov/pubmed/31847336 http://dx.doi.org/10.3390/pharmaceutics11120679 |
work_keys_str_mv | AT lkisseszter designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT berkoszilvia designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT gacsiattila designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT kovacsanita designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT katonagabor designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT soosjudit designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT csanyierzsebet designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT grofilona designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT harazinandras designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT delimariaa designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse AT budaiszucsmaria designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse |